The Central Drugs Standard Control Organisation (CDSCO) is accelerating the digital transformation of India’s pharmaceutical regulatory framework by piloting Artificial Intelligence (AI) across key regulatory processes and developing an end-to-end Digital Drug Regulatory System (DDRS). Announcing the initiative at the Global Drug Regulatory Conclave (GDRC) 2026, Dr. Rajeev Singh Raghuvanshi, Drugs Controller General of India (DCGI), said the first phase of the integrated digital platform will be rolled out within the next 18 months, creating a faster, transparent and data-driven regulatory ecosystem for the pharmaceutical and medical device industries.

How AI Is Already Transforming CDSCO’s Regulatory Processes

According to the DCGI, more than 99% of CDSCO’s regulatory processes have already been digitised, significantly improving transparency and reducing approval timelines. The organisation is now piloting AI-driven tools to automate reviewer allocation, pre-screen regulatory applications, support document evaluation, generate regulatory reports and strengthen pharmacovigilance and safety assessments. Officials said these AI-enabled systems are expected to reduce first-response timelines by up to 80% and lower overall processing time by around 40%, enabling faster regulatory decision-making without compromising patient safety.

What the Digital Drug Regulatory System (DDRS) Will Include

The upcoming Digital Drug Regulatory System (DDRS) will serve as a single-window digital platform for pharmaceutical companies, integrating the entire product lifecycle — from application submission and clinical trial approvals to manufacturing licences, Good Manufacturing Practice (GMP) inspections, Certificate of Pharmaceutical Product (CoPP) issuance and post-market surveillance. [Explore our GMP/CoPP Certification resource page]

QR Code Authentication: Faster Global Recognition for Exporters

As part of the digital reforms, GMP and CoPP certificates will now be issued with QR code-based authentication, allowing overseas regulators to instantly verify their authenticity and helping exporters save up to six months in overseas product registration processes.

Government Vision Behind the CDSCO Digital Drug Regulatory System

The announcement aligns with the Government of India’s broader vision of modernising the pharmaceutical regulatory ecosystem through digital governance and globally harmonised regulatory standards. Speaking virtually at GDRC 2026, Union Health Minister J.P. Nadda said India is building a future-ready regulatory framework that promotes healthcare innovation while maintaining the highest standards of quality, safety and efficacy.

The conclave, organised by Pharmexcil in collaboration with CDSCO, brought together regulatory authorities from more than 40 countries, including the United States, United Kingdom and Japan, to strengthen international regulatory cooperation and expand global recognition of the Indian Pharmacopoeia (IP). [Read more Pharma Regulatory Updates]

Industry Reaction to the CDSCO Digital Drug Regulatory System

Healthcare and regulatory experts have welcomed the initiative, stating that AI-enabled regulation and a fully integrated digital platform will significantly improve efficiency, transparency and compliance across India’s pharmaceutical sector. By combining artificial intelligence, digital authentication and end-to-end regulatory automation, CDSCO is expected to strengthen India’s position as a globally trusted pharmaceutical manufacturing hub while accelerating approvals, enhancing regulatory oversight and supporting the country’s vision of becoming a leader in digital health governance. [About Us / Newsroom]

Frequently Asked Questions

What is the CDSCO Digital Drug Regulatory System (DDRS)?

The DDRS is an upcoming single-window digital platform by CDSCO that will integrate the entire pharmaceutical product lifecycle – from application submission to post-market surveillance – using AI-driven tools.

When will the CDSCO Digital Drug Regulatory System be rolled out?

The first phase of the Digital Drug Regulatory System is expected to be rolled out within 18 months, as announced at the Global Drug Regulatory Conclave (GDRC) 2026.

How will AI improve CDSCO’s regulatory processes?

AI-driven tools are expected to reduce first-response timelines by up to 80% and lower overall processing time by around 40%, by automating reviewer allocation, application pre-screening, and document evaluation.

How does QR code authentication help pharmaceutical exporters?

QR code-based authentication on GMP and CoPP certificates allows overseas regulators to instantly verify their authenticity, helping exporters save up to six months in overseas product registration processes.